Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.71 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | ATIC | P31939 | 1/20 | 0.54 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14678117 | 0.85 | PGR (0.68) | PGRGPR119CACNA1BARFFAR1 | |
| SCHEMBL14684326 | 0.85 | PGR (0.58) | PGRGPR119CACNA1BARATIC | |
| SCHEMBL15474245 | 0.83 | FFAR1 (0.74) | PGRGPR119CACNA1BMAPTFFAR1 | |
| SCHEMBL5866185 | 0.81 | AR (0.56) | PGRGPR119CACNA1BARATIC | |
| SCHEMBL11028156 | 0.81 | PGR (0.64) | PGRGPR119ATICMEN1KMT2A | |
| SCHEMBL15472299 | 0.80 | PGR (0.63) | PGRGPR119CACNA1BFFAR1FFAR4 | |
| SCHEMBL28662441 | 0.79 | PGR (0.49) | PGRMAPTMEN1KMT2A | |
| SCHEMBL7572258 | 0.79 | CYP19A1 (0.75) | PGRARMAPTMEN1KMT2A | |
| SCHEMBL14645822 | 0.79 | CYP19A1 (0.75) | ARATICMEN1KMT2A | |
| SCHEMBL3792939 | 0.78 | F2 (0.62) | PGRCACNA1BARFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739139-B1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | UNIV NAT TAIWAN (TW) | 2019-09-25 | — | — | EP | disclosed |
| US-9216950-B2 | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-12-22 | — | — | US | disclosed |
| US-9216950-B2 | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-12-22 | — | — | US | disclosed |
| US-9090617-B1 | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-07-28 | — | — | US | disclosed |
| US-9090617-B1 | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-07-28 | — | — | US | disclosed |
| US-20150191467-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | RAND BIOSCIENCES (KR) | 2015-07-09 | — | — | US | disclosed |
| US-20150191467-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | RAND BIOSCIENCES (KR) | 2015-07-09 | — | — | US | disclosed |
| US-20140200239-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | NATIONAL TAIWAN UNIVERSITY (TW) | 2014-07-17 | — | — | US | disclosed |
| EP-2739139-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | National Taiwan University (TW) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013020014-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | NATIONAL TAIWAN UNIVERSITY (TW) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013020014-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | NATIONAL TAIWAN UNIVERSITY (TW) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191467-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | SRC, PTPRCAP, GRB2 | PGR 4181/4885GPR119 844/4885CACNA1B 2762/4885 |
| US-20140200239-A1 | AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME | SRC, PTPRCAP, GRB2 | PGR 4181/4885GPR119 844/4885CACNA1B 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.